- CDC Warns of Dangerous Infection Risk With EzriCare Eyedrops
- 52,000 Pounds of Sausage Products Recalled Due to Listeria Danger
- AHA News: 11 Things to Know to Save a Life With CPR
- AHA News: 11 cosas a saber para salvar una vida con RCP
- Ozempic: Dieters Who Use Scarce Diabetes Drug Could Face Side Effects
- Gallbladder & Bile Duct Cancers: Rare, Silent and Deadly. Know the Signs
- Many Young Americans Don’t Realize Heart Attacks Can Hit Them Too: Poll
- Poll Finds Many U.S. Women Confused About Medical Abortion
- Sports-Linked Cardiac Arrest Rare in Seniors, Study Finds
- Health Highlights: Feb. 1, 2023
Aptiom Approved to Treat Seizures

MONDAY, Nov. 11Aptiom (eslicarbazepine acetate) has been approved by the U.S. Food and Drug Administration as an add-on drug to help treat adults with partial epileptic seizures.
Epilepsy, caused by abnormal activity in the brain’s nerve cells, is diagnosed in some 200,000 people annually in the United States, the agency said in a news release. So-called “partial” seizures are the most common type of seizure among people with epilepsy, triggering possible symptoms including repetitive movement of limbs, unusual behavior and convulsions.
Aptiom’s safety and effectiveness were evaluated in three clinical studies. The most common side effects noted were dizziness, drowsiness, nausea, headache, double vision and loss of coordination.
As with other anti-epileptic drugs, Aptiom may trigger thoughts of suicide in a small number of users, the FDA said. People who take the drug should contact a doctor immediately if they have thoughts of suicide, or worsening anxiety or depression, the agency warned.
Aptiom is marketed by Sunovion Pharmaceuticals, based in Marlborough, Mass.
More information
To learn more about epilepsy, visit the U.S. Centers for Disease Control and Prevention.
Source: HealthDay
Copyright © 2023 HealthDay. All rights reserved.